India
· Delayed Price · Currency is INR AstraZeneca Pharma India Statistics
Total Valuation
AstraZeneca Pharma India has a market cap or net worth of INR 172.66 billion. The enterprise value is 167.65 billion.
| Market Cap | 172.66B |
| Enterprise Value | 167.65B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Jul 5, 2024 |
Share Statistics
AstraZeneca Pharma India has 25.00 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Shares Outstanding | 25.00M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 7.93% |
| Owned by Institutions (%) | 7.23% |
| Float | 4.16M |
Valuation Ratios
The trailing PE ratio is 180.07.
| PE Ratio | 180.07 |
| Forward PE | n/a |
| PS Ratio | 12.44 |
| PB Ratio | 24.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 174.89 |
| EV / Sales | 12.08 |
| EV / EBITDA | 106.94 |
| EV / EBIT | 117.94 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 122.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 13.54% |
| Revenue Per Employee | 14.76M |
| Profits Per Employee | 1.02M |
| Employee Count | 940 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +52.64% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +52.64% |
| 50-Day Moving Average | 6,763.11 |
| 200-Day Moving Average | 5,879.37 |
| Relative Strength Index (RSI) | 55.06 |
| Average Volume (20 Days) | 971 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca Pharma India had revenue of INR 13.88 billion and earned 958.60 million in profits. Earnings per share was 38.35.
| Revenue | 13.88B |
| Gross Profit | 6.67B |
| Operating Income | 1.42B |
| Pretax Income | 1.33B |
| Net Income | 958.60M |
| EBITDA | 1.54B |
| EBIT | 1.42B |
| Earnings Per Share (EPS) | 38.35 |
Balance Sheet
The company has 5.06 billion in cash and 45.90 million in debt, giving a net cash position of 5.01 billion or 200.39 per share.
| Cash & Cash Equivalents | 5.06B |
| Total Debt | 45.90M |
| Net Cash | 5.01B |
| Net Cash Per Share | 200.39 |
| Equity (Book Value) | 7.12B |
| Book Value Per Share | 284.77 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 48.06%, with operating and profit margins of 10.24% and 6.91%.
| Gross Margin | 48.06% |
| Operating Margin | 10.24% |
| Pretax Margin | 9.58% |
| Profit Margin | 6.91% |
| EBITDA Margin | 11.07% |
| EBIT Margin | 10.24% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 24.00, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | 24.00 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.38% |
| Earnings Yield | 0.56% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 15, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Jun 15, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |